Compare Merck & Co., Inc. (MRK) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Materials Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $132.78 (market cap $321.77B), while Materials Select Sector SPDR Fund trades at $52.69. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| MRK | XLB | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | — |
52-Week High | $131.84 | $53.62 |
52-Week Low | $77.60 | $42.23 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
XLB trades at $53.14, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support and oscillators showing mixed signals. The materials sector ETF benefits from infrastructure spending and AI-related demand, though recent articles suggest the cyclical recovery may be largely priced in. Dividend payments are scheduled for 2026.
The outlook for XLB remains positive due to sector tailwinds from infrastructure and manufacturing trends, though valuation concerns exist after recent gains. Key risks include cyclical sector exposure and potential overvaluation. Analyst sentiment appears cautiously optimistic with technical strength supporting near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
